170 related articles for article (PubMed ID: 3539384)
1. Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin.
Bregman CL; Williams PD
Cancer Chemother Pharmacol; 1986; 18(2):117-23. PubMed ID: 3539384
[TBL] [Abstract][Full Text] [Related]
2. Modification of immunoreactive EGF and EGF receptor after acute tubular necrosis induced by tobramycin or cisplatin.
Leonard I; Zanen J; Nonclercq D; Toubeau G; Heuson-Stiennon JA; Beckers JF; Falmagne P; Schaudies RP; Laurent G
Ren Fail; 1994; 16(5):583-608. PubMed ID: 7855315
[TBL] [Abstract][Full Text] [Related]
3. Renal tissue injury and proliferative response after successive treatments with anticancer platinum derivatives and tobramycin.
Nonclercq D; Toubeau G; Tulkens P; Heuson-Stiennon JA; Laurent G
Virchows Arch B Cell Pathol Incl Mol Pathol; 1990; 59(3):143-58. PubMed ID: 1980761
[TBL] [Abstract][Full Text] [Related]
4. Preclinical studies identifying carboplatin as a viable cisplatin alternative.
Harrap KR
Cancer Treat Rev; 1985 Sep; 12 Suppl A():21-33. PubMed ID: 3910219
[TBL] [Abstract][Full Text] [Related]
5. [Nephrotoxicity and myelotoxicity of antineoplastic Pt(II) and Pt(IV) coordination compounds in rats].
Horn U; Härtl A; Neuhaus G; Stöckel U; Schröer HP; Hoffmann H
Arch Geschwulstforsch; 1989; 59(4):245-50. PubMed ID: 2802932
[TBL] [Abstract][Full Text] [Related]
6. Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats.
Uehara T; Watanabe H; Itoh F; Inoue S; Koshida H; Nakamura M; Yamate J; Maruyama T
Arch Toxicol; 2005 Aug; 79(8):451-60. PubMed ID: 15856183
[TBL] [Abstract][Full Text] [Related]
7. In vivo biochemical indices of nephrotoxicity of platinum analogs tetraplatin, CHIP, and cisplatin in the Fischer 344 rat.
Smith MA; Smith JH; Litterst CL; Copley MP; Uozumi J; Boyd MR
Fundam Appl Toxicol; 1988 Jan; 10(1):62-72. PubMed ID: 3350230
[TBL] [Abstract][Full Text] [Related]
8. Tissue injury and repair in the rat kidney after exposure to cisplatin or carboplatin.
Nonclercq D; Toubeau G; Laurent G; Tulkens PM; Heuson-Stiennon JA
Exp Mol Pathol; 1989 Oct; 51(2):123-40. PubMed ID: 2680578
[TBL] [Abstract][Full Text] [Related]
9. Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents.
McKeage MJ; Morgan SE; Boxall FE; Murrer BA; Hard GC; Harrap KR
Br J Cancer; 1993 May; 67(5):996-1000. PubMed ID: 8494733
[TBL] [Abstract][Full Text] [Related]
10. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
11. Comparative toxicity and renal distribution of the platinum analogs tetraplatin, CHIP, and cisplatin at equimolar doses in the Fischer 344 rat.
Smith JH; Smith MA; Litterst CL; Copley MP; Uozumi J; Boyd MR
Fundam Appl Toxicol; 1988 Jan; 10(1):45-61. PubMed ID: 3350229
[TBL] [Abstract][Full Text] [Related]
12. [Study on nephrotoxicity in rats receiving cis-diammine-1,1-cyclobutane dicarboxylate platinum II--special reference to morphological changes].
Kimura S; Nakajima Y; Hasegawa S; Tazaki H
Nihon Hinyokika Gakkai Zasshi; 1989 Apr; 80(4):517-25. PubMed ID: 2664296
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway.
Wainford RD; Weaver RJ; Stewart KN; Brown P; Hawksworth GM
Toxicology; 2008 Jul; 249(2-3):184-93. PubMed ID: 18583013
[TBL] [Abstract][Full Text] [Related]
14. Comparative nephrotoxicity of a novel platinum compound, cisplatin, and carboplatin in male Wistar rats.
Wolfgang GH; Dominick MA; Walsh KM; Hoeschele JD; Pegg DG
Fundam Appl Toxicol; 1994 Jan; 22(1):73-9. PubMed ID: 8125216
[TBL] [Abstract][Full Text] [Related]
15. Lung tumour growth delay and normal tissue toxicity induced by three cytotoxic platinum drugs.
van Rongen E; Kal HB; Kuijpers WC; van Berkel AH
Strahlenther Onkol; 1992 May; 168(5):300-7. PubMed ID: 1598667
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of cisplatin and carboplatin on pharmacokinetics, nephrotoxicity and effect on renal nuclear DNA synthesis in rats.
Yasumasu T; Ueda T; Uozumi J; Mihara Y; Kumazawa J
Pharmacol Toxicol; 1992 Feb; 70(2):143-7. PubMed ID: 1508841
[TBL] [Abstract][Full Text] [Related]
17. [Experimental study on carboplatin toxicity--a comparison with cisplatin].
Suzuki K; Usami T; Sudoko H; Ohtawara Y; Tajima A; Kawabe K; Aso Y
Gan To Kagaku Ryoho; 1988 Jul; 15(7):2153-8. PubMed ID: 3293538
[TBL] [Abstract][Full Text] [Related]
18. The role of the renin-angiotensin system in cisplatin nephrotoxicity.
Deegan PM; Nolan C; Ryan MP; Basinger MA; Jones MM; Hande KR
Ren Fail; 1995 Nov; 17(6):665-74. PubMed ID: 8771239
[TBL] [Abstract][Full Text] [Related]
19. Differences in the sensitivity of Fischer and Sprague-Dawley rats to aminoglycoside nephrotoxicity.
Reinhard MK; Hottendorf GH; Powell ED
Toxicol Pathol; 1991; 19(1):66-71. PubMed ID: 2047709
[TBL] [Abstract][Full Text] [Related]
20. The effect of rebamipide on cisplatin-induced nephrotoxicity in rats.
Saad SY; Najjar TA; Al-Sohaibani MO
Pharmacol Res; 2000 Jul; 42(1):81-6. PubMed ID: 10860639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
